- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
New Payment Models Could Motivate Providers to Cut Wasteful Services
The overuse of pricey medical technology and medication presents a complex challenge for policymakers, hospitals and doctors trying to reduce costs.
The overuse of pricey medical technology and medication presents a complex challenge for policymakers, hospitals and doctors trying to reduce costs. But the payoff could be substantial, and early results of experiments by Medicare and Blue Cross and Blue Shield of Massachusetts suggest new payment models may be the motivation providers need to tackle the daunting task.
Unnecessary imaging, diagnostic and preventive tests (among other inappropriate services) inflated Medicare spending by $1.9 billion to $8.5 billion in 2009, researchers reported this week. The waste accounted for a small fraction of Medicare's overall expenditures that year—0.6% to 2.7%—but the study was limited to around two dozen overused medical services from hundreds that researchers considered.
Read the full story here: http://bit.ly/RHP4ah
Source: Modern Healthcare
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More
